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ATP-binding cassettetransporters form the largest family of membrane proteins in micro-organisms
where they are able to transport a wide variety of substrates against a concentration gradient, in an ATP-
dependent process. Two genes from the same putative Bacillus subtilis operon, yheI and yheH, encoding
possibly two different ABC transporters, were overexpressed in Escherichia coli in high yield, either separately
or jointly. Using membrane vesicles, it is shown here that both subunits were required to detect, (i) the
transport of four structurally unrelated drugs, and (ii) a vanadate-sensitive ATPase activity. Mutation of the
invariant Walker-A lysine to an alanine residue in both subunits led to an inactive transporter. Moreover,
after membrane solubilization by detergent, both wild-type subunits co-puriﬁed on a Ni-Agarose afﬁnity
column while only the YheH subunit contained a hexa-histidine tag. This shows that YheI and YheH are
indeed able to interact together to form a heterodimer. Importantly, expression of both yheI and yheH genes
in B. subtilis could be strongly stimulated by addition of sub-inhibitory concentrations of various unrelated
antibiotics. Therefore, B. subtilis YheI/YheH forms a new heterodimeric multidrug ABC transporter possibly
involved in multiple antibiotic resistance in vivo.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionABC (ATP-binding cassette) transporters belong to a large super-
family of membrane proteins widely spread among all living
organisms [1–3]. They are able to translocate, either as an import or
an export mechanism, a wide range of substrates across membranes
using ATP hydrolysis as a power source [4]. All ABC transporters share
the same basic architecture with two cytosolic nucleotide-binding
domains (NBDs) that bind and hydrolyze ATP, and two transmem-
brane domains (TMD) that translocate the substrates. These four
domains can be part of a single polypeptide (full-length transporters
such as human P-glycoprotein) or be borne on separate subunits, up to
four [5]. Some transporters have one NBD fused to a TMD and these
so-called half-size transporters work either as homodimers (two
identical half-size subunits assemble together to form a functional
transporter) or as heterodimers (two different half-size subunits
associate together as a functional transporter) [6,7]. While the TMDs
are quite variable in sequence and topology among ABC transporters,
their NBDs show a remarkable similar 3-D structure [8], resulting from
the conservation at the sequence level of several motifs including
notably the Walker A and B and the ABC signatures [9].
Drug resistance has been recognized as a major impediment in
therapy for a long time but the involvement of drug transporters as+33 4 38 78 54 94.
.
l rights reserved.major players in this mechanism, especially in multidrug resistance
(MDR) phenotypes, has only been gaining credit in recent years
[10,11]. In contrast to eukaryotes where identiﬁed MDR transporters
belong to the ABC family [12], the vast majority of bacterial MDR
transporters reported so far are secondary transporters [13]. However,
the discovery of the ﬁrst bacterial ABC transporter about ten years ago
by Konings' group, LmrA from Lactococcus lactis [14], and the advent of
the genomic era have paved the way to the study of many more
putative MDR bacterial ABC transporters. Hence, we and others have
participated in the characterisation of these new MDR transporters
including BmrA from B. subtilis [15], HorA from Lactobacillus brevis
[16], OmrA from Oenococcus oeni [17], and VcaM from Vibrio cholerae
[18]. These are all half-size transporters that presumably worked as
homodimers and this has been demonstrated biochemically for both
LmrA and BmrA [19,20] and conﬁrmed by 3-D structures of related
bacterial transporters, Sav1866 or MsbA [21,22]. Alternatively, it was
shown that two different half-size bacterial ABC transporters are
sometimes required to observe aMDR phenotype suggesting that they
work as heterodimers. These pairs include EfrA/B from Enterococcus
faecalis [23], LmrC/D from L. lactis [24] and AbcA/B from Biﬁdobacter-
ium breve [25] (see [26] for a recent review).
The genome of B. subtilis, the archetype of Gram positive bacteria,
encodes for at least 78 ABC transporters that have been split in 38
importers and 40 exporters, and classiﬁed into 11 sub-families
according to their putative function [27]. Of these, 8 ABC transpor-
ters of B. subtilis have been classiﬁed in the MDR-like sub-family
with 4 members predicted to function as homodimers, YvcC, YwjA,
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were putative heterodimers. We have shown that YvcC is indeed a
MDR ABC transporter and renamed it BmrA (for Bacillus multidrug
resistance ATP, [15], see above), while SunT belongs to the sublancin
operon and is likely involved in the export of the sublancin 168
lantibiotic [28]. For the putative heterodimeric ABC transporters of
this MDR-like sub-family of B. subtilis, little information is yet
available concerning their possible function, except for the CydD/C
proteins. They are encoded in the cydABCD operon which is
maximally expressed under low oxygen tension [29]. In E. coli, the
CydD/C transporter is required for the proper cytochrome bd quinol
assembly and it exports reductants into the periplasm [30].
Concerning the YheI/YheH couple, a recent report suggested that it
was somehow involved in the sporulation process of B. subtilis
because its overexpression reduced the sporulation efﬁciency
possibly by modulating the function of KinA [31]. On the other
hand, overexpression of B. subtilis yheI/H was observed in the
presence of few antibiotics [32,33], suggesting a possible role of
YheI/H in multiple drug resistance.
The aim of this work was to functionally characterize YheI/H, and
thanks to a high level of overexpression in E. coli, we show here that
these proteins associate to form a newmultidrug ABC transporter, the
ﬁrst one to function in B. subtilis as a heterodimer. Moreover, the
expression of both yheI/yheH in B. subtilis can be turned on by the
presence of many structurally unrelated drugs, which strongly hints at
a physiological role of YheI/YheH as an ABC transporter involved in
cellular detoxiﬁcation.
2. Materials and methods
2.1. Bacteria and growth conditions
B. subtilis 168 strain was used for yheI and yheH ampliﬁcation.
E. coli TOP10 (Invitrogen) and E. coli BL21(DE3) (Novagen) strainsFig. 1. Organization of the yheI/yheH operon in B. subtilis, and predicted topology with cons
codon is highlighted. B, the conserved motifs of the ABC transporter superfamily are indic
nucleotide-binding domain, respectively. The TMD contains 6 and 4 predicted α-helices forwere used for gene cloning and protein overexpression, respectively.
Unless otherwise stated, B. subtilis and E. coli cells were grown in Luria
Bertani (LB) medium at 37 °C.
2.2. Cloning and sequencing
Genomic DNA was prepared from B. subtilis cells by an adapted
cetyltrimethylammonium DNA puriﬁcation method [34]. YheI and
yheH genes (accession no. BG13041 and BG13040, respectively) were
ampliﬁed by PCR using Pfu Turbo DNA Polymerase (Stratagene)
(primers: YheI-5′AAG GAT CCG TTT TCA GTT TTG AAA AAG CTT GGC
TGG, YheI-3′ AACTC GAGTGC CCC TGC TCC CCC TTC TTC CGC, YheH-5′
AAG GAT CCG AAA ATA GGA AAA ACG TTA TGG AG, YheH-3′ AA CTC
GAG TGC AAT GGA ATG TTT CTG TCC C; restriction sites are
underlined). The YheI/YheH (YheI/H) construction was obtained by
DNA ampliﬁcation using YheI-5′ and YheH-3′ primers. Sequence
veriﬁcations were made by DNA sequencing (Genome Express
Corporation, France). The genes were cloned into pET21b(+) vector
(Novagen), allowing the addition of six consecutive histidine residues
on the carboxyl terminus of the proteins.
2.3. Site-directed mutagenesis of YheI/YheH
The pET21b(+)/YheI/H plasmid constructed as described above, was
usedasa template for site-directedmutagenesis using theQuikChange®
Site-Directed Mutagenesis Kit (Stratagene) according to manufacturer's
instructions. Primers used were as follows: K377A-YheI GT AAA ACC
GGTAGCGGAGCAACGACAATTATTAAGCAGC;K469A-YheHGGCCAT
ACC GGA TCA GGA GCT AGC TCG ATT TTG AAT CTT C. (the mutated
bases are underlined and the reverse-complementary primers are not
listed).
The pET21b(+)/YheI K377A/YheH K469A double mutant was
obtained by introducing the MscI/XhoI fragment from the K469A
construction into the plasmid coding for the K377A mutant.erved motifs in YheI and YheH. A, the overlap between yheI stop codon and yheH start
ated for both proteins; TMD and NBD correspond to the transmembrane domain and
YheI and YheH, respectively [27].
Table 1
Sequence comparison between YheI/YheH and selected ABC transporters
a Percentage of identical plus strongly similar residues were obtained from pairwise
sequence alignments using the Clustal W program on the http://npsa-pbil.ibcp.fr/ web
site with the predeﬁned parameters. In this program, the residues deﬁned as strongly
similar belong to either of the following groups (see also http://bips.u-strasbg.fr/fr/
Documentation/ClustalX/): Ser, Thr or Ala; Asn, Glu, Gln or Lys; Asn, His, Gln or Lys; Asn,
Asp, Glu orGln; Gln, His, Arg or Lys;Met, Ile, Leu andVal;Met, Ile, Leu and Phe;His or Tyr;
Phe, Trp or Tyr. Sequences used were obtained from the following web servers: Bacillus
subtilis YheI and YheH, http://genolist.pasteur.fr/SubtiList/index.html; Listeria
monocytogenes (Lmo1651 and 1652), http://genolist.pasteur.fr/ListiList/index.html;
Streptococcus pneumoniae strains R6 (Spr 1656 and 1657) and Tigr4 (SP 2073 and
2075), http://genolist.pasteur.fr/StreptoPneumoList/index.html; Serratia marcescens
SmdA and SmdB, http://www.ncbi.nlm.nih.gov/Genbank/ (accession codes,
BAF79679.1 and BAF79680.1, respectively); For the other sequences, the Swiss-Prot
entries (given in parenthesis) were used: MdlA and MdlB from E. coli (P77265 and
P0AAG5, respectively); LmrC and LmrD from Lactococcus lactis (Q9CIP6_LACLA and
Q9CIP5_LACLA, respectively); EfrA, EfrB, EF1732 and EF1733 from Enterococcus faecalis
(Q82ZX7_ENTFA, Q82ZX8_ENTFA, Q834D4_ENTFA and Q834D3_ENTFA, respectively).
The top six transporters are the most closely related ones and, among them, the
Lmo1652/Lmo1651 pair is somehow involved in the virulence of Listeria [46], and
insertional inactivation of lmo1652 leads to a strongly attenuated in vivo intracellular
replication of the knockout mutant [47]. For the EF1733/EF1732 pair, its expression has
been shown to be strongly up-regulated by addition of either erythromycin or
chloramphenicol [48]. The three remaining transporters are more distantly related to
YheI/YheH but they all have been shown to be involved in MDR phenotypes
[23,24,43,44].
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preparation
Freshly transformed colonies were inoculated into Turbo Broth™
medium (AthenaES) and grown at 37 °C with shaking at 220 rpm.
0.7 mM isopropyl β-D-thiogalactopyranoside (IPTG) was added when
the OD600 nm reached 1.8. The culture was further grown overnight at
25 °C and bacteria were collected by low-speed centrifugation.
Subsequent bacterial lysis and IMV preparation were carried out
using a French press as previously described [35]. Protein over-
expression was checked by Coomassie brilliant blue-stained sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).
2.5. Puriﬁcation of YheI/YheH
IMV containing overexpressed YheI and hexahistidine-tagged
YheH were prepared as described above and solubilized for 2 h on
ice in buffer A (50 mM Tris–HCl pH 8, 15% glycerol, 100 mM NaCl,
5 mM β-mercaptoethanol) supplemented with 10 mM imidazole and
1% N-dodecyl-β-D-maltoside (DDM) at a protein concentration of
1 mg/ml. After centrifugation for 1 h at 200,000g, the supernatant was
incubated with 1/10 (v/v) of Ni2+-NTA resin (Qiagen) for 1 h. Resinwas
washedwith 20 column volumes of buffer A supplementedwith 0.05%
DDM and 20mM imidazole. Elutionwas carried out in the same buffer
but in the presence of 250 mM imidazole.
2.6. ATPase activity
The ATPase activity was measured by Pi release using a
colorimetric method described by Heinonen and Lahti [36], slightly
modiﬁed by Tomaszek and Schuster [37]. Brieﬂy, membrane control or
membranes containing overexpressed YheI, YheH or YheI/YheH
(200 μg of proteins) were incubated at 30 °C for 30 min in 50 mM
Hepes/KOH pH 8.0, 7 mM ATP, 7 mM MgCl2, 2 mM NaN3, and in the
presence when indicated of 200 μM ortho-vanadate (Sigma) (ﬁnal
volume of 200 μl). Membranes obtained from an E. coli strain
transformed with an empty pET21 plasmid were used as a control.
After an incubation period, 4 volumes of freshly prepared acetone-
acid-molybdate (AAM) reagent (3 parts acetone, 1 part 10.0 N H2SO4
and 1 part 15.0 mM ammonium molybdate) were added. 45 s after
AAM addition, 0.4 volumes of 1 M citric acid were added. The
absorbance of the phosphomolybdate complex was measured at
355 nm.
2.7. Fluorescent drugs transport
For drug transport assays, variations in ﬂuorescence intensity were
monitored with a Photon Technology International Quanta Master I
ﬂuorimeter. Excitation and emission wavelengths were of 355 and
457 nm for Hoechst 33342 (2′-[4-ethoxyphenyl]-5-[4-methyl-1-
piperazinyl]-2, 5′-bis-1H-benzimidazole; Sigma), 480 and 590 nm
for doxorubicin (Sigma) and 608 and 690 nm for mitoxantrone
(Sigma), respectively. Membrane vesicles (200 μg of protein) were
added into a 2 ml cuvette containing 1 ml of 50 mM Hepes/KOH pH
8.0, 2 mM MgCl2, 8.5 mM NaCl, 40 μg pyruvate kinase (Roche) and
4 mM phosphoenolpyruvate. After 1 min incubation at 30 °C, the drug
was added, and its ﬂuorescencewas recorded for 1–2min. ATP (2mM)
was then added and the ﬂuorescence intensity was monitored for
several minutes.
2.8. BCECF uptake into inside-out membrane vesicles
Accumulation of BCECF (2′,7′-bis-(3-carboxyethyl)-5-(and-6)-
carboxyﬂuorescein; Biochemika) in IMV was performed in buffer
containing 50 mM Hepes/KOH pH 8, 250 mM sucrose, 8.5 mM NaCl,
7 mM MgCl2, 10 mM phosphoenolpyruvate, 20 μg/ml pyruvatekinase (Roche), with addition of 7 mM ATP or 7 mM AMPPNP in
control samples. BCECF was added to a ﬁnal concentration of
12.5 μM. The samples (with membrane vesicles at 1 mg protein/ml)
were incubated at 30 °C for 30 min in darkness. The reaction was
stopped by addition of an iced-cold stop solution (50 mM Hepes/
KOH pH 8, 250 mM sucrose, 20 mM EDTA) to give a ﬁnal EDTA
concentration of 12 mM, followed by a subsequent centrifugation
(100,000 ×g, 30 min). The supernatant was removed and the vesicle
pellet was washed three times with the stop solution before being
resuspended in 1 ml of 1% (v/v) Triton X-100 in 50 mM Hepes/KOH
pH 8. BCECF ﬂuorescence was then measured with the wavelengths
set at 494 nm and 521 nm for the excitation and emission,
respectively. Fluorescence intensity was found to be linear with
BCECF concentration in the range considered. Experiments were
performed in triplicate.
2.9. Measurement of expression values of yheI and yheH
The relative mRNA levels of the genes yheI and yheH in B. subtilis
were determined using whole-genome microarrays based on a two-
color ﬂuorescence technology (Eurogentec, Seraing, Belgium). B.
subtilis 168 growing in Belitzki minimal medium [38], to OD600=0.4
at 37 °C were treated with antibiotics for 10 and 40 min, respectively.
The preparation of untreated and antibiotics-treated samples, the
image acquisition via the Axon GenePix® 4000A confocal laser
scanner (Axon Instruments, Foster City, CA) and the relative signal
Table 2
Antibiotics-induced expression of yheI and yheH in B. subtilis
Compound Concentration (μg/ml) Time (min) Expression ratio
yheI yheH
Azithromycin⁎ 2 10 2.61 2.51
40 6.88 6.52
Cerulenin 32 10 1.57 2.23
40 2.86 4.63
Chloramphenicol⁎ 4 10 2.98 5.20
40 2.25 3.54
Doxycycline⁎ 0.3 10 6.42 5.92
40 n.d. n.d.
Erythromycin⁎ 0.1 10 9.27 12.82
40 6.17 7.91
Fluorouracil 0.2 10 1.24 1.09
40 3.09 3.07
Fusidic acid⁎ 0.08 10 6.08 4.38
40 9.30 5.99
Gentamicin⁎ 0.26 40 1.18 1.06
40 1.73 2.12
Linezolid⁎ 0.5 10 10.93 6.20
40 20.70 13.65
Nalidixic acid 25 10 1.51 1.12
40 2.38 1.63
TAN 1057⁎ 0.048 10 4.84 5.55
40 1.22 1.16
Average expression values (ratios) of yheI and yheH higher than the value 2.00 derived
from B. subtilis transcriptomemeasurements with 46 different antibiotics. In addition to
the eleven compounds listed above, the following antibiotics were tested:
corallopyronin, streptovaricin, rifampicin, actinonin, gentamicin, kanamycin,
pactamycin, puromycin, moiramide B, triclosan, azaserine, novobiocin, ciproﬂoxacin,
sulfamethoxazole, trimetoprim, trovaﬂoxacin, moxiﬂoxacin, cefoxitin, methicillin,
mersacidin, oxacillin, ristocetin, ramoplanin, vancomycin, phenyl-thiazolylurea
derivative, mupirocin, actinomycin D, ethidium bromide, N-ethylmaleimide,
nitrofurantoin, nisin, netropsin, polymyxin B, showdomycin, tunicamycin.
⁎ Compounds known as protein biosynthesis inhibitors. n. d., not determined.
Fig. 2. Overexpression of YheI and/or YheH in inside-out E. coli vesicles and co-
puriﬁcation of YheI/YheH. A, 10% SDS-PAGE stained with Coomassie Blue of inside-out
membrane vesicles prepared from an E. coli strain containing the pET21b empty
plasmid (lane 1), or overexpressing YheI (lane 2), YheH (lane 3) or both YheI/YheH (lane
4); 8 μg of membrane proteins were loaded into each lane. Black arrowhead, YheH; grey
arrowhead, YheI. The small difference in electrophoretic mobility for YheI (lane 2 as
compared to lane 4) is due to the presence of an additional (His)6-tag in lane 2. In the
case of YheH, an additional T7-tag is present in lane 3 as compared to lane 4. B, 10% SDS-
PAGE stained with Coomassie Blue of inside-out membrane vesicles prepared from an E.
coli strain overexpressing YheI and YheH-6xHis (lane 5); soluble fraction obtained after
incubation with 1% N-dodecyl-β-D-maltoside (lane 6); fraction eluted from the Ni2+-
NTA column in the presence of 250 mM imidazole (lane 7). The positions of the
molecular weight markers are indicated on each side of the ﬁgure (in kDa).
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software Expressionist® Pro 2.0 (Genedata, Basel) have been
published previously [39,40]. Each average expression value (ratio)
was derived from triplicates of microarray experiments.
3. Results and discussion
3.1. The yheI/yheH operon in B. subtilis
Analysis of the genome of B. subtilis 168 strain using the Subtilist
web server (http://genolist.pasteur.fr/SubtiList/) revealed the pre-
sence of two overlapping open reading frames for the yheI and yheH
genes. Thus, the STOP codon (TGA) of yheI became part of the ATG start
codon of the downstream yheH gene, by a frameshift of one nucleotide
(Fig. 1A). Overlapping has been widely observed in organisms with a
limited genome size, and although it was initially considered as a
mechanism to increase the amount of information per unit length
[41], it is also now viewed as away to tightly coordinate the expression
of overlapping genes [42]. Both yheI and yheH genes encode half-size
ABC transporters containing a putative transmembrane region
followed by a nucleotide-binding domain. The latter shows the
characteristic motifs of the ABC superfamily, namely the Walker A
and B motifs and the ABC signature (Fig. 1B). Therefore, the genomic
organization of their coding regions and the predicted topology of the
two putative half-size transporters, YheI and YheH, suggest the
possibility that they might interact together to form a functional
heterodimeric unit.
A search for orthologues of YheI/YheH in other bacterial species
was undertaken. Notwithstanding the related Bacilli species which all
possess closely related pairs of ABC transporters, orthologues of YheI/
YheH were also found in some pathogenic species such as Gram
positives Listeria monocytogenes (Lmo1652/Lmo1651), Streptococcus
pneumoniae (Spr1657/Spr1656) and Enterococcus faecalis (EF1733/EF1732), or Gram negatives Serratia marcescens (SmdA/SmdB) and E.
coli (MdlA/MdlB; see Table 1). Within this closely related cluster, only
the SmdA/SmdB heterodimer has been shown very recently to likely
confer a MDR phenotype using an E. coli reporter strain [45].
3.2. YheI/yheH induction upon antibiotics exposure
Previous results have shown that addition of sub-inhibitory
concentrations of few drugs might induce the expression of both
yheI and yheH [32,33]. Reporter strains were then built using the
upstream sequence of yheI gene [49] or yheH gene [50], but induction
by antibiotics was only seen for the former strain, which is in
agreement with both genes being co-transcribed from the same
promoter (upstream sequence of yheI). We then decided to conﬁrm
and extend these studies by addressing the effect of 46 different
antibiotics on the transcriptome of B. subtilis. As shown in Table 2,
eleven of these were able to increase signiﬁcantly the expression level
of both yheI/yheH. Importantly, we found no other ABC transporters or
secondary transporters putatively, or known to be, involved in MDR
phenotypes with such a high level of induction upon drug exposure
(data not shown), despite the occurrence of many hypothetical MDR
transporters in B. subtilis genome [51]. Notably, and in accord with
previous results obtained with the yheI promoter [49], most of the
compounds that increase the expression of both genes are antibiotics
that target the ribosomes. This might suggest that yheI/yheH induction
is somehow a consequence of a ribosome-related signaling pathway,
and it has been proposed that the antibiotic-inhibited ribosome may
affect the transcription apparatus by triggering the stringent response
[52]. Consistent with this idea, yheI/yheH overexpression has also
been reported during the stringent response of B. subtilis [53].
Accordingly, treatment of B. subtilis with antibiotics affecting the
50S and/or 30S ribosomal subunits has been reported to induce
accumulation of (p)ppGpp, a hallmark of the stringent response [54].
However, the transcriptome data obtained here with antibiotics
affecting protein synthesis (data not shown) show no correlation
with the transcriptional program triggered by the stringent response
in B. subtilis [53]. This implies that the signaling pathways elicited by
Fig. 4. Transport of Hoechst 33342. 2 μMHoechst 33342 was added at t∼100 s to inside-
out membrane vesicles containing overexpressed wild-type YheI plus YheH (traces a
and b), YheI (trace c), YheH (trace d), or YheI K377A/YheH K469A double mutant (trace
e). Trace b was obtained in the presence of 200 μM vanadate. After ∼ 150 s of further
incubation, 2 mM ATP was added to initiate Hoechst 33342 transport.
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different.
3.3. Overexpression of YheI and/or YheH in E. coli and ATPase activities of
membrane vesicles
To investigate the function of YheI and YheH, these proteins were
overexpressed in a BL21(DE3) E. coli strain, either separately or jointly,
and inside-out membrane vesicles were prepared. A very high level of
expressionwas obtained for the two proteins expressed alone, YheI or
YheH, when their respective gene was cloned separately into an E. coli
expression vector under the control of a T7 promoter, and each protein
appeared correctly addressed to the membrane (Fig. 2A). Similarly,
when the whole B. subtilis yheI/yheH operonwas cloned into the same
E. coli expression vector, both proteins YheI and YheH were readily
overexpressed (Fig. 2A, lane 4). This result is clearly different from the
scenario observed in the case of the DrrA/DrrB ABC transporter from
M. tuberculosis where the original overlapping of drrA and drrB
genes was detrimental to the co-expression of both subunits in E. coli;
the co-expression of both subunits was only observed after the
creation of an artiﬁcial operon, with a new ribosome-binding site
being introduced between both genes [55]. Besides, the level of
expression reported here for YheI/YheH is much higher than that
reported for two heterodimeric half-size ABC transporters that have
been previously overexpressed in Lactococcus lactis, LmrC/D from
L. lactis and AbcA/B from Biﬁdobacterium breve [24,25], but in either
case the two genes were not overlapping at the genomic level. To our
knowledge, this is probably the highest expression level reported so
far for an ABC transporter, that seems even better than that of BmrA in
E. coli which amounted to ∼50% of total membrane proteins [15].
The functionality of the overexpressed proteins was then studied
bymeasuring the ATPase activity of the different vesicles. As shown in
Fig. 3, vesicles containing both YheI/YheH had a ∼2.5–3 fold higher
ATPase activity compared to vesicles containing each protein alone.
This ATPase activity attributable to YheI/YheHwas reduced to ∼20% in
the presence of 200 μM ortho-vanadate, a well-known inhibitor of
ABC transporters [56,57]. Membrane vesicles prepared from E. coli
cells containing an empty pET21b plasmid (control vesicles) showed a
higher level of background ATPase activity than the vesicles contain-
ing each protein alone, but it should be noted that the same amount of
total membrane proteins were used for each assay leading probably to
an overestimation of the ATPase activity due to ‘contaminating’
ATPases in these control vesicles. In contrast to the vesicles containing
both YheI and YheH, none of the other vesicles showed an ATPaseFig. 3. ATPase activity of E. coli inside-out membrane vesicles containing overexpressed
YheI, YheH or both YheI+YheH wild-type or double mutant (YheI K377A/YheH K469A).
Control vesicles were obtained from an E. coli strain transformed with an empty pET21
plasmid. The ATPase activities were measured as described under “Materials and
methods”, in the absence (empty boxes) or presence (ﬁlled boxes) of 200 μM ortho-
vanadate. The values are expressed as the mean±SD for three independent
experiments.activity readily inhibited by vanadate, thus indicating that if YheI or
YheH alone were able to hydrolyse ATP to some extent, this hydrolysis
would be unrelated to that normally displayed by native ABC
transporters. An additional control was made where the invariant
Walker A lysine, known to be essential in ABC transporters [58], was
mutated to alanine in both YheI and YheH, thus creating a K377A
(YheI)/K469A (YheH) double mutant. Although the membrane
vesicles prepared from an E. coli strain overexpressing the K377A/
K469A double mutant showed a slightly reduced level of mutated
subunits as compared to an E. coli strain overexpressing the wild-type
YheI/YheH transporter (data not shown), the level of ATPase activity of
the vesicles containing the double mutant was strongly reduced to
∼25% of that of the wild-type membranes. More importantly, the level
of ATPase activity of the vesicles containing the double mutant was
unaffected by vanadate addition. Overall, these data are consistent
with the hypothesis that YheI and YheH are required together to
create a functional transporter.
3.4. YheI and YheH physically interact to form a heterodimer
The possible interaction between YheI and YheH was then
investigated by trying to co-purify YheI and YheH while only the
latter subunit contained a poly-histidine tag. First, membrane
fractions containing both YheI and YheH were solubilized in the
presence of N-dodecyl-β-D-maltoside and the soluble fraction was
loaded onto a nickel afﬁnity chromatography column. After a washing
step, both YheI and YheH co-eluted from the column in the presence
of high concentration of imidazole (Fig. 2B). This result conﬁrms that a
physical interaction was maintained between YheI and YheH
throughout the procedure and that both proteins form a stable
heterodimer. Similar conclusions were drawn from the studies of
LmrC/LmrD and AbcA/AbcB [24,25]. However, it is possible that some
loss of the untagged subunit (i.e. the YheI subunit) had occurred here
because when we performed an extensive washing step, the amount
of YheI subunit recovered decreased as compared to the YheH subunit
(data not shown), showing that the stability of the heterodimer can be
challenged by the puriﬁcation procedure.
3.5. YheI/YheH is a MDR transporter
Next, transport assays of typical ﬂuorescent substrates of MDR ABC
transporters were performed using inside-out membrane vesicles
[59], according to the continuous ﬂuorescence assay described for
the study of these transporters. Among the tested compounds,
the strongest transport activity was seen with Hoechst 33342. This
Fig. 5. A. Transport of doxorubicin (A) and mitoxantrone (B). A, After ∼ 100 s incubation
at 30 °C, 10 μM doxorubicin was added to inside-out membrane vesicles containing
overexpressed wild-type YheI/YheH, in the absence (a) or presence of 200 μM vanadate
(b), or YheI K377A/YheH K469A double mutant (c). Transport of doxorubicin was
initiated by addition of 2mMATP at t∼250 s. B, 5 μMmitoxantronewas added to inside-
out membrane vesicles containing overexpressed wild-type YheI/YheH, in the absence
(a) or presence of 500 μM vanadate (b), or YheI K377A/YheH K469A double mutant (c).
Transport of mitoxantrone was initiated by addition of 2 mM ATP at t∼300 s.
Fig. 6. BCECF uptake into inside-out membrane vesicles. Inside-out membrane vesicles
(1 mg/ml) containing wild-type YheI/YheH (wt) or YheI K377A/YheH K469A double
mutant (K377A/K469A) were incubated at 30 °C with 12.5 μM BCECF for 30 min in the
presence of either 7 mM ATP or 7 mM AMPPNP as a control (wt+AMPPNP). After
centrifugation and washing steps, the pellet containing the vesicles was resuspended in
1% Triton X-100, and BCECF accumulation was estimated by ﬂuorescence quantiﬁcation
(see Materials and methods).
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brane but not in an aqueous medium, allowing movement of the dye
to be monitored by real time ﬂuorescence intensity [24,35,60–62]. As
shown in Fig. 4, transport of the ﬂuorophore by YheI/YheH from the
membrane into the lumen of the vesicles was revealed by a rapid
ﬂuorescence decay observed when ATP was added, and this activity
was highly reduced in the presence of vanadate (compare traces a and
b, respectively). In contrast, membrane vesicles containing theWalker
A lysine double mutant, YheI K377A/YheH K469A, showed no
transport activity at all (trace e). Likewise, vesicles containing YheI
or YheH alone did not show any signiﬁcant transport activity of
Hoechst 33342 (traces c and d, respectively). Using a similar approach
tomonitor the transport of other ﬂuorescent substrates [15], the wild-
type YheI/YheH was also shown to transport doxorubicin and
mitoxantrone (Fig. 5A and B, respectively, traces a), while the Walker
A lysine double mutant failed to transport any of these drugs (Fig. 5A
and B, traces c). Again, addition of vanadate strongly attenuated the
transport of doxorubicin or mitoxantrone by wild-type YheI/YheH
(traces b).
Finally, we used an accumulation assay described for vesicles
enriched in multidrug-related protein MRP1 [63], to monitor the
transport of ﬂuorescent BCECF by wild-type YheI/YheH (Fig. 6).
Replacing ATP by a non-hydrolysable analogue, AMPPNP, signiﬁcantly
reduced the transport of this drug by the wild-type YheI/YheH (by
∼35%) and a similar result was obtained in the presence of vanadate(not shown). Moreover, this transport ability was even further
reduced (to ∼ 55%) when the YheI K377A/YheH K469A double mutant
was used.
In conclusion, we have shown here that YheI/YheH forms a
heterodimeric ABC transporter able to work as a new multidrug
transporter in vitro, with four structurally unrelated drugs identiﬁed
here as its substrates. The drug transport ability was impaired in the
double Walker A mutant, or strongly reduced by vanadate addition in
the wild-type transporter, showing that ATP hydrolysis is required to
power YheI/YheH, in agreement with results obtained on two other
MDR bacterial ABC transporters, BmrA or LmrC/D [15,64]. Due to the
abundance of putative, or proven, MDR transporters in many bacteria
(for instance 20 transporters out of 37 putative MDR were indeed
capable of transport drugs in E. coli, [65]), it has been proposed that
most of them have another physiological function and that their drug
transport abilities are merely an opportunistic feature [66,67]. This
was exempliﬁed with the Bmr and Blt secondary transporters of Ba-
cillus subtilis: they share 51% of sequence identity and both
transporters can act as a MDR transporter with similar multidrug
speciﬁcity [68]. However, in contrast to Bmr whose expression is
upregulated bymany drugs and is likely to be a ‘true’MDR transporter,
Blt expression is not induced by drugs [68], and this transporter is
more likely devoted to spermidine efﬂux in Bacillus than to multidrug
efﬂux [69].
On the other hand, classiﬁcation of new a transporter as a
multidrug transporter based solely on a high degree of sequence
similarity with a related transporter known to be a MDR should not be
taken for granted. Indeed, it has been shown that although human
MDR1 and MDR2 share ∼75% identity (∼70% in the case of
orthologous transporters, mdr1 and mdr2, from mouse), the former
only is able to efﬂux drugs while the latter fails to confer a MDR
phenotype and its physiological role has been assigned to a
phosphatidylcholine translocase [70,71]. Therefore, bioinformatic
classiﬁcation can give us some clues about the possible function of
unknown transporters but only biochemical evidence should be used
to ascertain the role of putative MDR transporters.
In the case of yheI/yheH, it is noteworthy that their expression level
can be strongly induced upon exposure to several classes of
structurally unrelated antibiotics. Such a high level of induction
brought about by some antibiotics was unmatched for any other
putative or proven MDR transporters in B. subtilis that belonged either
to the ABC superfamily or to secondary transporter superfamilies [32],
621C. Torres et al. / Biochimica et Biophysica Acta 1788 (2009) 615–622including the well known multidrug secondary transporter Bmr [72].
To the best of our knowledge, this is the ﬁrst time that a putative
multidrug bacterial ABC transporter is shown to be so much up-
regulated by different drugs. Based on the assumption that the only
true bacterial multidrug transporters are those that are up-regulated
by many drugs (see [66] for a review), our results suggest that the
YheI/YheH pair functions in vivo as amultidrug transporter. In order to
investigate this further, we created a ΔyheI/yheH mutant of Bacillus
subtilis and compared its growth properties to that of wild-type B.
subtilis in the presence of different concentrations of many drugs,
including antibiotics listed in Table 2. In contrast to what might be
expected, no clear difference was observed between both strains
regarding their sensitivity towards the tested compounds (results not
shown). Although this could be interpreted as a lack of MDR function
for the YheI/YheH pair in vivo, it is noteworthy that B. subtilis is one of
themicro-organisms that contain the highest amount of putativeMDR
transporters in its genome (N30; [73]). Thus, it is possible that the
presence of other MDR genes mask the effect of deleting the yheI/yheH
in this knockout mutant. Moreover, a recent report using a collection
of ∼4,000 single-gene knockouts in E. coli revealed that among the 20
exporters which have been shown previously to extrude drugs when
overexpressed in a drug-sensitive E. coli host mutant [65], only the
deletion of the well characterized AcrAB pump led to a signiﬁcant
increase of sensitivity towards three of seven antimicrobial com-
pounds tested [74]. This latter report emphasizes how difﬁcult it can
be to ascertain the physiological role of putative MDR transporters
based on knockout experiments. Congruent with this, a ΔbmrA
(formely known as ΔyvcC) Bacillus mutant also showed no increase
in sensitivity as compared to the wild-type strain whatever anti-
microbial compound was screened (Cédric Orelle and J.-M. J,
unpublished results), and despite the ability of BmrA to function
efﬁciently in vitro as a multidrug transporter [15,35]. Thus, regarding
the YheI/YheH pair, although its features are consistent with a
function in multidrug efﬂux, we cannot rule out that its physiological
role might be linked to a more speciﬁc cellular pathway triggered by
the exposure to antibiotics, and further work will be needed to
investigate this point. With the ever-growing number of bacterial
genomes available, it is likely that the discovery of heterodimeric
(either ‘true’ or opportunistic) multidrug ABC transporters in many
more bacteria, including pathogenic species, will become an emerging
theme in this research ﬁeld.
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